Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein

Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology

Volumn 105, Issue 6, 2014, Pages 1139-1148

  Scavone, Paola ^a   Umpiérrez, Ana ^a   Rial, Analía ^b   Chabalgoity, José A ^b   Zunino, Pablo ^a  

^a INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

^b DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

Author keywords

Adjuvant; Flagellin; MR P fimbriae; Urinary tract infection

Indexed keywords

FIMBRIA PROTEIN; FLAGELLIN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; MRPA PROTEIN; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; IMMUNOLOGICAL ADJUVANT; MRPA PROTEIN, PROTEUS MIRABILIS;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL COLONIZATION; CELL STIMULATION; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG PURIFICATION; FEMALE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSTIMULATION; MONOTHERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEUS INFECTION; RENAL PROTECTION; SPLEEN CELL; URINARY TRACT INFECTION; ANIMAL; BIOSYNTHESIS; BLADDER; BLOOD; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; KIDNEY; MICROBIOLOGY; MONONUCLEAR CELL; PROTEUS INFECTIONS; PROTEUS MIRABILIS; URINARY TRACT INFECTIONS; URINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; DRUG ANTAGONISM; FLAGELLIN; INTERLEUKIN-10; KIDNEY; LEUKOCYTES, MONONUCLEAR; MICE; PROTEUS INFECTIONS; PROTEUS MIRABILIS; URINARY BLADDER; URINARY TRACT INFECTIONS;

EID: 84901284028     PISSN: 00036072     EISSN: 15729699     Source Type: Journal    
DOI: 10.1007/s10482-014-0175-7     Document Type: Article

References (45)

1. Asadi Karam MR, Oloomi M, Mahdavi M, Habibi M, Bouzari S (2013) Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. Vaccine 31:1210-1216
2. Bates JT, Uematsu S, Akira S, Mizel SB (2009) Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J Immunol 182:7539-7547
3. Braga CJ, Rittner GM, Muñoz Henao JE, Teixeira AF, Massis LM, Sbrogio-Almeida ME, Taborda CP, Travassos LR, Ferreira LC (2009) Paracoccidioides brasiliensis vaccine formulations based on the gp43-derived P10 sequence and the Salmonella enterica FliC flagellin. Infect Immun 77:1700-1707
4. Brunner R, Jensen-Jarolim E, Pali-Schöll I (2010) The ABC of clinical and experimental adjuvants - a brief overview. Immunol Lett 128:29-35
5. Chan CY, St John AL, Abraham SN (2013) Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 38:349-359
6. Cunningham AF, Khan M, Ball J, Toellner KM, Serre K, Mohr E, MacLenna IC (2004) Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol 34:2986-2995 (Pubitemid 39549378)
7. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J (1992) Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 175:671-682
8. Didierlaurent A, Ferrero I, Otten LA, Dubois B, Reinhardt M, Carlsen H, Blomhoff R, Akira S, Kraehenbuhl JP, Sirard JC (2004) Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol 172:6922-6930 (Pubitemid 38669131)
9. Dielubanza EJ, Schaeffer AJ (2011) Urinary tract infections in women. Med Clin N Am 95:27-41
10. Duan Q, Zhou M, Zhu L, Zhu G (2012) Flagella and bacterial pathogenicity. J Basic Microbiol 52:1-8
11. Duell BL, Tan CK, Carey AJ, Wu F, Cripps AW, Ulett GC (2012) Recent insights into microbial triggers of interleukin-10 production in the host and the impact on infectious disease pathogenesis. FEMS Immunol Med Microbiol 64:295-313
12. Errea A, Moreno G, Sisti F, Fernandez J, Rumbo M, Hozbor DF (2010) Mucosal innate response stimulation induced by lipopolysaccharide protects against Bordetella pertussis colonization. Med Microbiol Immunol 199:103-108
13. Faezi S, Safarloo M, Behrouz B, Aminmozafari N, Nikokar I, Mahdavi M (2012) Comparison between active and passive immunization with flagellin-based subunit vaccine from Pseudomonas aeruginosa in burned-mouse model. Iran J Clin Infect Dis 7:10-16
14. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099-1103 (Pubitemid 32391041)
15. Honko AN, Mizel SB (2004) Mucosal administration of flagellin induces innate immunity in the mouse lung. Infect Immun 72:676-679
16. Jacobsen SM, Stickler DJ, Mobley HLT, Shirtliff ME (2008) Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev 21:26-59 (Pubitemid 351160009)
17. Jarchum I, Liu M, Lipuma L, Pamer EG (2011) Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect Immun 79:1498-1503
18. Johnson JR (1996) Treatment and Prevention of urinary tract infections. In: Mobley HLT, Warren JW (eds) Urinary tract infections: molecular pathogenesis and clinical management. ASM Press, Washington, pp 95-118
19. Kinnebrew MA, Ubeda C, Zenewicz LA, Smith N, Flavell RA, Pamer EG (2010) Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-resistant Enterococcus infection. J Infect Dis 201:534-543
20. Lee SE, Kim SY, Jeong BC, Kim YR, Bae SJ, Ahn OS, Lee JJ, Song HC, Kim JM, Choy HE, Chung SS, Kweon MN, Rhee JH (2006) A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 74:694-702 (Pubitemid 43023125)
21. Legnani-Fajardo C, Zunino P, Algorta G, Laborde HF (1991) Antigenic and immunogenic activity of flagella and fimbriae preparations from uropathogenic Proteus mirabilis. Can J Microbiol 37:325-328
22. Legnani-Fajardo C, Zunino P, Piccini C, Allen A, Maskell D (1996) Defined mutants of Proteus mirabilis lacking flagella cause ascending urinary tract infection in mice. Microb Pathog 21:395-405 (Pubitemid 26387323)
23. Li X, Erbe JL, Lockatell CV, Johnson DE, Jobling MG, Holmes RK, Mobley HLT (2004) Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis. Infect Immun 72:7306-7310 (Pubitemid 39552402)
24. Mizel SB, Bates JT (2010) Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 185:5677-5682
25. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR (1990) Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248:1230-1234
26. Muñoz N, Van Maele L, Marques JM, Rial A, Sirard JC, Chabalgoity JA (2010) Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect Immun 78:4226-4233
27. Nicolle LE (2005) Catheter related urinary tract infection. Drugs Aging 22:627-639
28. Nielubowicz GR, Mobley HLT (2010) Host-pathogen interactions in urinary tract infection. Nat Rev Urol 7:430-441
29. Pellegrino R, Galvalisi U, Scavone P, Sosa V, Zunino P (2003) Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections. FEMS Immunol Med Microbiol 15:103-110 (Pubitemid 36515091)
30. Rather PN (2005) Swarmer cell differentiation in Proteus mirabilis. Environ Microbiol 7:1065-1073
31. Salyers AA, Whitt DD (1994) Bacterial pathogenesis, a molecular approach. ASM Press, Washington
32. Scavone P, Sosa V, Pellegrino R, Galvalisi U, Zunino P (2004) Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins. Microbes Infect 6:853-860 (Pubitemid 39055546)
33. Scavone P, Miyoshi A, Rial A, Chabalgoity A, Langella P, Azevedo V, Zunino P (2007) Intranasal immunization with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice. Microbes Infect 9:821-828 (Pubitemid 46901040)
34. Scavone P, Rial A, Umpiérrez A, Chabalgoity A, Zunino P (2009) Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract. Microbiol Immunol 53:233-240
35. Scavone P, Umpiérrez A, Maskell DJ, Zunino P (2011) Nasal immunization with attenuated Salmonella Typhimurium expressing an MrpA-TetC fusion protein significantly reduces Proteus mirabilis colonization in the mouse urinary tract. J Med Microbiol 60:899-904
36. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Frujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85 (Pubitemid 16258399)
37. Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett SL, Cookson BT, Aderem A (2003) Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 4:1247-1253 (Pubitemid 37540694)
38. Stamm WE, Martin SM, Bennett JV (1977) Epidemiology of nosocomial infections due to Gram-negative bacilli: aspects relevant to development and use of vaccines. J Infect Dis 136(Suppl):S151-S160 (Pubitemid 8171415)
39. Studier FW, Moffatt BA (1985) Use of a bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 189:113-130
40. Subramanian N, Qadri A (2006) Lysophospholipid sensing triggers secretion of flagellin from pathogenic salmonella. Nat Immunol 7:583-589 (Pubitemid 43797339)
41. Tarahomjoo S (2014) Utilizing bacterial flagellins against infectious diseases and cancers. Antonie Van Leeuwenhoek 105:275-288
42. Umpiérrez A, Scavone P, Romanin D, Marqués JM, Chabalgoity JA, Rumbo M, Zunino P (2013) Innate immune responses to Proteus mirabilis flagellin in the urinary tract. Microbes Infect 15:688-696
43. Warren JW, Tenney JH, Hoopes JM, Muncie HL, Anthony WC (1982) A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis 146:719-723 (Pubitemid 13211866)
44. Yu FS, Cornicelli MD, Kovach MA, Newstead MW, Zeng X, Kumar A, Gao N, Yoon SG, Gallo RL, Standiford TJ (2010) Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J Immunol 185:1142-1149
45. Zunino P, Geymonat L, Allen AG, Legnani-Fajardo C, Maskell DJ (2000) Virulence of a Proteusmirabilis ATF isogenicmutant is not impaired in a mouse model of ascending urinary tract infection. FEMS Immunol Med Microbiol 29:137-143